Shifting disease burden and increasing pressure to cap healthcare costs have fueled China's interest in developing biosimilars, with the government creating a favorable environment for biosimilars to flourish. China has been at the top of the strategic agenda for multinationals, while the technical gap of biosimilar development between multinational and local players is narrowing.
The most recent deal was a strategic partnership formed by Sanofi and Taiwan-listed JHL Biotech Inc
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?